Muduma G, Saunders R, Odeyemi I, PLoS ONE 2016; 11(11): e0160421.. Systematic review and meta-analysis of tacrolimus versus ciclosporin as primary immunosuppression after liver transplant.
ClinicoEconomics and Outcomes Research 2016; 8: 559-71., Bae JP, Boye KS, Norrbacka K, , . Evaluating health-related quality of life in type 1 diabetes: a systematic literature review of utilities for adults with type 1 diabetes.
Roze S, Duteil E, Journal of Medical Economics 2016; 19(8): 742-9, de Portu S, , de Brouwer BF, Reznik Y, de Valk HW. Cost-effectiveness of continuous subcutaneous insulin infusion in people with type 2 diabetes in the Netherlands.
Bruhn D, Martin AA, Tavares R, Journal of Medical Economics 2016; 19(7): 672-83., . Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US.
Muduma G, Odeyemi I, Journal of Medical Economics 2016; 19(10): 995-1002.. A cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK.
Roze S, Journal of Medical Economics 2016; 19(3): 236-4., , Cook M, Jethwa M, de Portu S, Pickup JC. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a UK perspective.
Roussel R, Martinez L, Vandebrouck T, Douik H, Emiel P, Guery M, Journal of Medical Economics 2016; 19(2): 121-34., . Evaluation of the long-term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France.
Muduma G, Odeyemi I, Advances in Therapy 2016; 33(3): 345-56., . Review of the clinical and economic burden of antibody-mediated rejection in renal transplant recipients.
Roze S, Diabetes Technology & Therapeutics 2016; 18(2): 75-84., , Payet V, de Portu S, Papo N, Cucherat M, Hanaire H. Cost-effectiveness of sensor-augmented pump therapy with low glucose suspend versus standard insulin pump therapy in two different patient populations with type 1 diabetes in France.
Muduma G, Odeyemi I, Drugs Real World Outcomes 2016; 3: 61-8.. Evaluating the cost-effectiveness of prolonged-release tacrolimus relative to immediate-release tacrolimus in liver transplant patients based on data from routine clinical practice.